Regorafenib (BAY 73-4506)

Catalog No.S1178 Synonyms: Fluoro-Sorafenib

Regorafenib (BAY 73-4506) Chemical Structure

Molecular Weight(MW): 482.82

Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 470 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.
Targets
RET [1]
(Cell-free assay)
Raf-1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
Kit [1]
(Cell-free assay)
VEGFR1 [1]
(Cell-free assay)
1.5 nM 2.5 nM 4.2 nM 7 nM 13 nM
In vitro

Regorafenib strongly prevents VEGFR2 autophosphorylation in NIH-3T3/VEGFR2 cells with IC50 of 3 nM. In HAoSMCs, regorafenib suppress PDGFR-β autophosphorylation after stimulation with PDGF-BB, with an IC50 of 90 nM. Regorafenib also inhibits FGFR signaling in MCF-7 breast cancer (BC) cells stimulated with FGF10. Regorafenib very potently inhibited the mutant receptors KITK642E and RETC634W, with IC50 of approximately 20 nM and 10 nM, respectively. Regorafenib inhibits the proliferation of VEGF165-stimulated HUVECs, with an IC50 of approximately 3 nM. Regorafenib prevents the proliferation of FGF2-stimulated HUVECs and of PDGF-BB-stimulated HAoSMCs with IC50 of 127 nM and 146 nM, respectively. [1] Regorafenib targets both tumor cell proliferation and tumor vasculature through inhibition of receptors of tyrosine kinases (VEGFR, KIT, RET, FGFR, and PDGFR) and serine/threonine kinases (Raf and p38MAPK). [2] Regorafenib suppresses growth of human Hep3B, PLC/PRF/5 and HepG2 cells in a concentration- and time-dependent manner. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Hep3B Mlj5RZBweHSxc3nzJGF{e2G7 M4XxWlHjiJN3wrFOwG0> M{[ydFQ5KGh? Moj6bY5pcWKrdIOgZ4VtdCCpcn;3eIg> MYCyOlMzQTZyOB?=
PLC/PRF/5  MULBdI9xfG:|aYOgRZN{[Xl? MV6x5qCUPcLizszN NHPzWXA1QCCq NXvD[pNpcW6qaXLpeJMh[2WubDDndo94fGh? MmToNlY{Ojl4MEi=
HepG2  NXfFUo93SXCxcITvd4l{KEG|c3H5 NYHXdmQyOeLCk{ZCpO69VQ>? NXznc29xPDhiaB?= MVPpcohq[mm2czDj[YxtKGe{b4f0bC=> MlzFNlY{Ojl4MEi=
HEK293 NIqyZllHfW6ldHnvckBCe3OjeR?= M37oXFAvPeLCid88US=> MYKyM|QwPiCq NWjleFRkemWmdXPld{BIWlB5ODDlfJBz\XO|aX;u MUSyOVg2QDB|Mh?=
GEO NF\vPVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVqybJRGOC5yMT2yNEDPxE1? NGe3V3A6PiCq MWrEUXNQ NXnQUoExcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1HIVlI2QDN6M{mx
SW48 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVywMlAyNTJyIN88US=> NHTj[W06PiCq NHf6RllFVVOR NWG1RWhWcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mni3NlU5Ozh|OUG=
HT29 M2LQdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\RW|AvODFvMkCg{txO NXrLXpdyQTZiaB?= MmewSG1UVw>? MmPrbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MYKyOVg{QDN7MR?=
SW480 NX3WZ3lRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH[zWW0xNjBzLUKwJO69VQ>? MUm5OkBp M2\oWGROW09? MXnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MY[yOVg{QDN7MR?=
SW620 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfNNE4xOS1{MDFOwG0> NXnUUlR6QTZiaB?= MUXEUXNQ NWLXTnZTcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MoLLNlU5Ozh|OUG=
HCT116 M{i2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrF[404OC5yMT2yNEDPxE1? M1nHZVk3KGh? M{XQZWROW09? MV3pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M1\TN|I2QDN6M{mx
LOVO NWDYSWluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLofog5OC5yMT2yNEDPxE1? NIH5[JU6PiCq MmX1SG1UVw>? MXnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M3jK[|I2QDN6M{mx
HCT150 MoHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\0Z3JkOC5yMT2yNEDPxE1? NEDhSlQ6PiCq Ml3zSG1UVw>? NFzvdnJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MlXUNlU5Ozh|OUG=
SW48-CR M1fnbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{iwbFAvODFvMkCg{txO M{i4d|k3KGh? MXLEUXNQ MmPjbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MkK2NlU5Ozh|OUG=
GEO-CR MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[wMlAyNTJyIN88US=> NXPkVXluQTZiaB?= MlrZSG1UVw>? NYm5[po3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MY[yOVg{QDN7MR?=
KB-31 NEfHc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fabWlEPTB;NT61xtExNjNibl2= NUHn[GhMOjV5NUOzOlE>
KB-G2 MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HZN2lEPTB;OT6xxtExNjFibl2= NYDBZ2N2OjV5NUOzOlE>
LLC-PK1 M4DqXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{W0bGlEPTB;NEKuNOKyOy5{IH7N NXTsN2VFOjV5NUOzOlE>
LLC-PK1/MRP2 NVfyVGxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTQfpdKSzVyPUiyMlTDuTJwNzDuUS=> NFj4N5ozPTd3M{O2NS=>
HEK293 NH7QbINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTFzLkFCtVEvOiCwTR?= M4jVfVI2PzV|M{[x
HEK293/OATP1B1 MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHFTWM2OD14LkNCtVAvOyCwTR?= Ml3PNlU4PTN|NkG=
HROC18 NWHlOpg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTFwMzFOwG0> Mn3ONlU{ODl7MUS=
HROC24 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTRwNjFOwG0> M1XrPFI2OzB7OUG0
HROC43 NUjxe4JuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTVwMzFOwG0> NGHs[FkzPTNyOUmxOC=>
HROC46 M1zJdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjNNHlKSzVyPUKuOEDPxE1? MVWyOVMxQTlzNB?=
RJ345 NVntN5dtTnWwY4Tpc44hSXO|YYm= MYKwMlUwPSEQvF2= NX3vZoxIOjRiaB?= M1ziO2ROW09? NVPDSYtscW6qaXLpeJMhfGinIHPlcIwhdWmpcnH0bY9v M4HzWFI2OjV|OUm0
RJ348 NYfNOoY6TnWwY4Tpc44hSXO|YYm= NVPIb49[OC53L{Wg{txO NXHBPHRZOjRiaB?= Ml22SG1UVw>? Mn[wbY5pcWKrdIOgeIhmKGOnbHygcYloemG2aX;u MYGyOVI2Ozl7NB?=
MCF-7 MoDTSpVv[3Srb36gRZN{[Xl? NGDXSHIxNjVxNTFOwG0> M4HxTlI1KGh? MlSwSG1UVw>? MkW2bY5pcWKrdIOgeIhmKGOnbHygcYloemG2aX;u NHLHSpUzPTJ3M{m5OC=>
MDA-MB-231 NV;JRY9sTnWwY4Tpc44hSXO|YYm= NYPw[ZIxOC53L{Wg{txO NGj5WGEzPCCq MnfJSG1UVw>? M4nNOYlvcGmkaYTzJJRp\SClZXzsJI1q\3KjdHnvci=> MV[yOVI2Ozl7NB?=
HT15 M3fkVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;iPWwyNTJyIN88US=> NX[1Zmx7PDhiaB?= NWHCU2VtcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NW\nUlZoOjVyN{GwNVg>
DLD1 MmSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXKxMVIxKM7:TR?= NVftO2k5PDhiaB?= NIjlZ4tqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Mom2NlUxPzFyMUi=
HT-29 Mm\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDZT4EyNTJyIN88US=> NVTtW|VXPDhiaB?= MV3pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MVeyOVA4OTBzOB?=
Hct-116 MmnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPnRY9POS1{MDFOwG0> MV[0PEBp NHTZR5BqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NYrHOpFWOjVyN{GwNVg>
HT15 NWeySnJpSXCxcITvd4l{KEG|c3H5 M{DjUVEuOTBizszN M4r5d|Q5KGh? MXPpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MnrnNlUxPzFyMUi=
DLD1 NGj1UmNCeG:ydH;zbZMhSXO|YYm= MnLBNU0yOCEQvF2= MWm0PEBp NGT1PVhqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NG\XNo8zPTB5MUCxPC=>
HT-29 MY\BdI9xfG:|aYOgRZN{[Xl? NGK0T2wyNTFyIN88US=> MnvVOFghcA>? MYTpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MUeyOVA4OTBzOB?=
Hct-116 M1HV[GFxd3C2b4Ppd{BCe3OjeR?= NUPVeZhJOS1zMDFOwG0> M1nKO|Q5KGh? MVjpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MYCyOVA4OTBzOB?=
GBM5 NVjGfZgzSXCxcITvd4l{KEG|c3H5 MnXRNE426oDVMT6w5qCK|ryP NWHYUXNJOjRiaB?= M{Lu[GROW09? NUn4Znp5cW62ZYLhZ5R{KHerdHigcIFx[XSrbnniJJRwKGmwZIXj[UBk\WyuIHTlZZRp NYTKbXNXOjR7MUGyNVU>
GBM6 NH64WlNCeG:ydH;zbZMhSXO|YYm= NHzrb3kxNjYkgKOxMlDjiIoQvF2= MVuyOEBp MnrDSG1UVw>? M2nB[IlvfGW{YXP0d{B4cXSqIHzhdIF1cW6rYjD0c{BqdmS3Y3WgZ4VtdCCmZXH0bC=> MnPMNlQ6OTF{MUW=
GBM12 NGCxV|RCeG:ydH;zbZMhSXO|YYm= MWmwMlXjiJNzLkFihKnPxE1? MXSyOEBp MY\EUXNQ Mo\5bY51\XKjY4TzJJdqfGhibHHwZZRqdmmkIITvJIlv\HWlZTDj[YxtKGSnYYTo M1LwRVI1QTFzMkG1
GBM14  M{O1fmFxd3C2b4Ppd{BCe3OjeR?= M1G3S|AvPeLCk{GuNQKBkc7:TR?= NX32cFFROjRiaB?= NEXjbplFVVOR NETOUGpqdnSncnHjeJMhf2m2aDDsZZBifGmwaXKgeI8hcW6mdXPlJINmdGxiZHXheIg> M{\2RVI1QTFzMkG1
Hep3B MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;vS2RMOeLCk{KuOeKh|ryP NF7aTIIzPC92OD:3NkBp MlrJbY5pcWKrdIOgZ4VtdCCpcn;3eIg> MkjkNlQ5QDV6OUC=
PLC/PRF/5  NV\EdnQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvTWosy6oDVMj61xsDPxE1? MlnvNlQwPDhxN{KgbC=> M3rFTYlvcGmkaYTzJINmdGxiZ4Lve5Rp M2HCcVI1QDh3OEmw
HepG2  NV:1dXc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGH2NIIy6oDVMj61xsDPxE1? MkHJNlQwPDhxN{KgbC=> MoWzbY5pcWKrdIOgZ4VtdCCpcn;3eIg> NELMXlUzPDh6NUi5NC=>
HCT116  M1zhR2Z2dmO2aX;uJGF{e2G7 MmP0NVAwOjBxNECg{txO M3HySlI1KGh? MUfpcoR2[2W|IGDVUWEheHKxdHXpckBidmRibWLORUBmgHC{ZYPzbY9vKGmwIHGg[I9{\S1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? M4jVdFI1PzZ|NkGx
Lim2405 NXzDN2NTTnWwY4Tpc44hSXO|YYm= M3Ls[|QxKM7:TR?= MXWyOEBp MUnpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> Mn60NlQ4PjN4MUG=
LoVo MonhSpVv[3Srb36gRZN{[Xl? NHfTb4k1OCEQvF2= MoeyNlQhcA>? NUjZdoNncW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m| MWKyOFc3OzZzMR?=
Lim1215 MVTGeY5kfGmxbjDBd5NigQ>? NXzXcI5iPDBizszN MWOyOEBp MlrQbY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ MlXPNlQ4PjN4MUG=
SW48 NEOzUYtHfW6ldHnvckBCe3OjeR?= MojEOFAh|ryP M{DoVFI1KGh? NEjr[IVqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? NHrVW3MzPDd4M{[xNS=>
RKO  NICxfHpHfW6ldHnvckBCe3OjeR?= MVK0NEDPxE1? MWCyOEBp NVnhd3ZbcW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m| MUKyOFc3OzZzMR?=
SW837 M4G0cWZ2dmO2aX;uJGF{e2G7 NXPk[XQyPDBizszN M1v3UVI1KGh? Mnz2bY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ NUHET2o1OjR5NkO2NVE>
SW1463 NFTYSpZHfW6ldHnvckBCe3OjeR?= NEjQUoY1OCEQvF2= NIXLVHUzPCCq Moi3bY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ MXmyOFc3OzZzMR?=
SW480 MWjGeY5kfGmxbjDBd5NigQ>? MnznOFAh|ryP M4nrXlI1KGh? MYHpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> NH\IemIzPDd4M{[xNS=>
Vaco432 M3fvVGZ2dmO2aX;uJGF{e2G7 MV20NEDPxE1? M1TDSFI1KGh? NHfXTmNqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? NH;UfXQzPDd4M{[xNS=>
Vaco400 MVzGeY5kfGmxbjDBd5NigQ>? MoLCOFAh|ryP M3P4[lI1KGh? NEflVotqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? NYDxUWF3OjR5NkO2NVE>
DLD1 M1fRVmZ2dmO2aX;uJGF{e2G7 Mn;yOFAh|ryP MnvLNlQhcA>? M2HPR4lv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? MYiyOFc3OzZzMR?=
HT29  M3r1SGZ2dmO2aX;uJGF{e2G7 MljkOFAh|ryP MkPSNlQhcA>? MlrabY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ M{C2XlI1PzZ|NkGx
PLC/PRF/5  MkfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnj5NgKBmzYEtV2= MXeyOE81QC95MjDo MV\pcohq[mm2czDj[YxtKGe{b4f0bC=> MV2yN|E3QTF2OB?=
HepG2 MmXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmL0NgKBmzYEtV2= NHLibJAzPC92OD:3NkBp MV7pcohq[mm2czDj[YxtKGe{b4f0bC=> NW\6dYZNOjNzNkmxOFg>
Hep3B  MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPvNFMy6oDVNdM1US=> NWnFd4VwOjRxNEivO|IhcA>? M1LOXolvcGmkaYTzJINmdGxiZ4Lve5Rp MUmyN|E3QTF2OB?=

... Click to View More Cell Line Experimental Data

In vivo Regorafenib reveals potent dose-dependent TGI in various preclinical human xenograft models in mice, with tumor shrinkages in breast MDA-MB-231 and renal 786-O carcinoma models. Regorafenib prevents not only the growth of syngeneic primary 4T1 breast tumors growing orthotopically in the fat pad, but also suppresses the formation of tumor metastasis in the lung. [1]

Protocol

Kinase Assay:[1]
+ Expand

Kinase assays:

In vitro assays using recombinant VEGFR2 (murine aa785–aa1367), VEGFR3 (murine aa818–aa1363), PDGFRβ (aa561–aa1106), Raf-1 (aa305–aa648) and BRafV600E (aa409–aa765) kinase domains are performed. Initial in vitro kinase inhibition profiling is performed at a fixed 1 μM Regorafenib concentration. Inhibitory concentration of 50% (IC50) values are determined from selected responding kinases, e.g., VEGFR1 and RET. TIE2 kinase inhibition is measured with a homogeneous time-resolved fluorescence (HTRF) assay using a recombinant fusion protein of glutathione-S-transferase, the intracellular domain of TIE2 and the peptide biotin-Ahx-EPKDDAYPLYSDFG as substrate.
Cell Research:[1]
+ Expand
  • Cell lines: GIST 882 and TT cells
  • Concentrations: 5 nM-10 μM
  • Incubation Time: 96 hours
  • Method: For proliferation assays, GIST 882 and TT cells are grown in RPMI medium containing L-glutamine, and MDA-MB-231, HepG2 and A375 cells in DMEM always containing 10% hiFBS. Cells are trypsinized, plated at 5×104 cells/well in 96-well plates in complete media containing 10% FBS and grown overnight at 37 °C. The next day, vehicle or Regorafenib serially diluted in complete growth media to between 10 μM and 5 nM final concentrations, and 0.2% DMSO, is added and incubation is continued for 96 hours. Cell proliferation is quantified.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female athymic NCr nu/nu mice with Colo-205, MDA-MB-231 or 786-O
  • Formulation: PEG400/125 mM aqueous methanesulfonic acid (80/20) or polypropylene glycol/PEG400/Pluronic F68 (42.5/42.5/15 + 20% Aqua)
  • Dosages: 3 mg/kg, 10 mg/kg, 30 mg/kg, 100 mg/kg
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 97 mg/mL (200.9 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 482.82
Formula

C21H15ClF4N4O3

CAS No. 755037-03-7
Storage powder
Synonyms Fluoro-Sorafenib

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02795156 Recruiting Non-small Cell Lung Carcinoma|Urothelial Carcinoma|Gastrointestinal Carcinoma, Non-colon|Upper Aerodigestive Tract Carcinoma SCRI Development Innovations, LLC|Foundation Medicine|Boehringer Ingelheim|Bayer September 28, 2016 Phase 2
NCT03042689 Not yet recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Bayer January 2017 Phase 1
NCT02910843 Not yet recruiting Rectal Cancer Swiss Group for Clinical Cancer Research December 2016 Phase 1
NCT02940223 Not yet recruiting Malignant Neoplasms of Independent (Primary) Multiple Sites|Metastatic Colorectal Cancer M.D. Anderson Cancer Center|Bayer December 2016 Phase 2
NCT02955940 Enrolling by invitation Pancreatic Cancer|Colorectal Cancer|Breastcancer|Lung Cancer Non-Small Cell Incyte Corporation November 2016 Phase 2
NCT02889328 Recruiting Gastrointestinal Stromal Tumors (GISTs) Asan Medical Center September 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) supplier | purchase Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) cost | Regorafenib (BAY 73-4506) manufacturer | order Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID